AVEO gets US FDA approval for Fotivda to treat renal cell carcinoma
AVEO Oncology has received the US Food and Drug Administration (FDA) approval for Fotivda (tivozanib) to treat a type of renal cell carcinoma (RCC). The US FDA indicated
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More XAVEO Oncology has received the US Food and Drug Administration (FDA) approval for Fotivda (tivozanib) to treat a type of renal cell carcinoma (RCC). The US FDA indicated
Takeda has acquired Maverick Therapeutics, a biopharmaceutical firm focused on conditionally active bispecific T-cell targeted immunotherapies, for about $525m. With the acquisition, Takeda will get Maverick’s T-cell engager
Dutch health technology firm Royal Philips has partnered with the US-based openDoctor to deliver an integrated radiology patient engagement platform. As part of the collaboration, openDoctor’s real-time patient
Eli Lilly and Company has entered into a research collaboration and license agreement with biotechnology firm Biolojic Design to discover and develop a new antibody-based therapy for diabetes.
US-based health care company Baxter International and mRNA-based therapeutics and vaccines maker Moderna have reached an agreement for the latter’s Covid-19 Vaccine. Under the partnership, Baxter BioPharma Solutions
US-based health technology firm Abbott has received the US Food and Drug Administration (FDA) Emergency Use Authorisation (EUA) for its Alinity m Resp-4-Plex molecular assay. Alinity m Resp-4-Plex
Kite, a subsidiary of Gilead Sciences, has received the US Food and Drug Administration (FDA) accelerated approval for its Yescarta (axicabtagene ciloleucel) to treat a type of follicular
Novartis has reached a preliminary agreement with CureVac to manufacture the mRNA and bulk drug product for the latter’s Covid-19 vaccine candidate CVnCoV. The companies are currently under
UK-based AI-driven pharmatech Exscientia has closed $100m in a Series C investment round, joined by funds managed by BlackRock. The company’s existing investors including Novo Holdings, Evotec, Bristol
Pfizer has received the expanded US Food and Drug Administration (FDA) approval for Lorbrena (lorlatinib) to include treatment of a type of non-small cell lung cancer (NSCLC). The